The at-the-market offering structure allows Q32 Bio to raise capital opportunistically but creates ongoing dilution pressure. The 3% commission is standard but adds to the cost of capital. With a market cap of $104M, this offering represents a significant dilution event. The stock may face downward pressure as the market anticipates continuous share sales. Monitor the pace of sales and how the company deploys the capital toward its bempikibart clinical trials.
Price Chart
Executive Summary
Q32 Bio Inc. (QTTB) has filed a 424B5 prospectus supplement to register the at-the-market offering of up to $14.2 million in common stock through Cantor Fitzgerald. The offering allows the company to sell shares from time to time at prevailing market prices, with Cantor earning a 3% commission on sales. The company intends to use the proceeds for working capital and advancing its lead drug candidate, bempikibart, into future clinical trials for alopecia areata.
Key Facts
- Q32 Bio is offering up to $14,200,000 in common stock through an at-the-market offering via Cantor Fitzgerald
- The offering has no minimum amount and will be sold at prevailing market prices, with Cantor earning a 3% commission
- Proceeds will be used for working capital and advancing bempikibart into future clinical trials for alopecia areata
- The company has a market cap of $104M and the public float is approximately $74.2M
- The offering will result in immediate dilution of $3.39 per share to new investors
Financial Impact
Up to $14,200,000 in dilution from new share issuance
Risk Factors
- Significant dilution to existing shareholders as up to $14.2M in new shares are issued
- Ongoing share sales through the at-the-market program could create sustained downward pressure on the stock price
- The company has a history of dilutive financings, including a $10.5M offering in the prior 12 months
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-129424 |
| Document: 0001193125-26-129424-index-headers.html | 0001193125-26-129424 |
| Document: 0001193125-26-129424-index.html | 0001193125-26-129424 |
| Document: 0001193125-26-129424.txt | 0001193125-26-129424 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $10.91 $10.47 | ▼ −4.03% | ▼ −4.14% | $8.23 (−24.56%) |
Aug 27, 2026 5w ago | Insider Cluster | $16.15 $12.80 | ▼ −20.74% | ▼ −21.01% | $8.23 (−49.04%) |
Aug 5, 2026 8w ago | 8-K | $16.49 $15.37 | ▼ −6.79% | ▼ −7.14% | $8.23 (−50.09%) |
Jul 15, 2026 11w ago | Press Release | $15.70 $15.08 | ▲ +3.95% | ▲ +2.97% | $8.23 (+47.58%) |
Jul 14, 2026 11w ago | EFFECT | $18.46 $15.04 | ▼ −18.53% | ▼ −17.23% | $8.23 (−55.42%) |
Jul 13, 2026 11w ago | 8-K | $21.38 $15.05 | ▼ −29.61% | ▼ −28.82% | $8.23 (−61.51%) |
Jul 13, 2026 11w ago | 8-K | $21.38 $15.05 | ▼ −29.61% | ▼ −28.82% | $8.23 (−61.51%) |
Jun 25, 2026 14w ago | S-3 | $13.17 $13.09 | ▼ −0.61% | ▼ −2.77% | $8.23 (−37.51%) |
Jun 2, 2026 17w ago | Insider Cluster | $12.64 $11.89 | ▼ −5.93% | ▼ −2.97% | $8.23 (−34.89%) |
May 5, 2026 21w ago | 8-K | $5.14 $5.81 | ▲ +13.04% | ▲ +11.05% | $8.23 (+60.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access